Inactive Instrument

Entasis Therapeutics Holdings Inc.

Equities

ETTX

US2936141033

Biotechnology & Medical Research

Entasis Therapeutics Holdings Inc. Announces Resignation of Michael Gutch as Chief Financial Officer, Effective February 24, 2022

January 15, 2022 at 02:31 am IST

Entasis Therapeutics Holdings Inc. announced on January 10, 2022 accepted the resignation of Michael Gutch, Chief Financial Officer. Dr. Gutch will continue to serve as Chief Financial Officer until February 24, 2022, on which date his employment with the Company shall terminate.

Latest news about Entasis Therapeutics Holdings Inc.

Entasis Therapeutics Holdings Inc. Presents Efficacy and Safety Data from Landmark Phase 3 ATTACK Trial At IDWEEK 2022	19/22/19	CI
Entasis Therapeutics Holdings Inc.(NasdaqGM:ETTX) dropped from S&P TMI Index	13/22/13	CI
Innoviva Acquires Remaining Stake in Entasis Therapeutics	12/22/12	MT
Entasis Therapeutics Holdings Inc.(NasdaqGM:ETTX) dropped from NASDAQ Composite Index	11/22/11	CI
Innoviva, Inc. completed the acquisition of the remaining 40% stake in Entasis Therapeutics Holdings Inc. from a group of shareholders.	11/22/11	CI
Entasis Therapeutics Holdings Inc.(NasdaqGM:ETTX) dropped from Russell 3000E Value Index	24/22/24	CI
Entasis Therapeutics Holdings Inc.(NasdaqGM:ETTX) dropped from Russell Microcap Value Index	24/22/24	CI
Innoviva to Acquire Remaining Stake in Entasis Therapeutics for $2.20 Per Share in Cash; Entasis Stock Surges Pre-Bell	23/22/23	MT
Entasis Therapeutics Holdings Inc. Presents Data Highlights from Phase 3 Attack Trial At 2022 American Thoracic Society Annual Conference	17/22/17	CI
Cantor Fitzgerald Downgrades Entasis Therapeutics Holdings to Neutral From Overweight, Adjusts Price Target to $2 From $5	06/22/06	MT
Wedbush Lifts Price Target on Entasis Therapeutics Holdings to $2 From $1.80 on Innoviva's Revised Bid, Maintains Neutral Rating	28/22/28	MT
Entasis Therapeutics Holdings Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	27/22/27	CI
Entasis Therapeutics Presents Efficacy and Safety Data from Landmark Phase 3 ATTACK Trial at ECCMID 2022 Conference	26/22/26	CI
Top Premarket Decliners	26/22/26	MT
Alliance Global Downgrades Entasis Therapeutics Holdings to Neutral From Buy	16/22/16	MT
Wedbush Cuts Entasis Therapeutics Holdings to Neutral From Outperform, Price Target to $1.80 From $9, Citing Acquisition Proposal	08/22/08	MT
HC Wainwright Downgrades Entasis Therapeutics Holdings to Neutral from Buy, Adjusts Price Target to $1.80 from $6	04/22/04	MT
Entasis Therapeutics Holdings Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	03/22/03	CI
Entasis Therapeutics Holdings Inc. Auditor Raises 'Going Concern' Doubt	03/22/03	CI
Entasis Therapeutics Holdings CFO Resigns	26/22/26	MT
Entasis Therapeutics Holdings Inc. Announces Executive Changes	26/22/26	CI
Entasis Therapeutics Holdings Inc. announced that it has received $15 million in funding from Innoviva Strategic Opportunities LLC	18/22/18	CI
Entasis Therapeutics Holdings Inc. announced that it expects to receive $15 million in funding from Innoviva Strategic Opportunities LLC	17/22/17	CI
Entasis Therapeutics Receives Cash Buyout Proposal From Innoviva at $1.80/Share; Shares Slide After-Hours	03/22/03	MT
Innoviva, Inc. entered into a definitive agreement to acquire to acquire remaining 40% stake in Entasis Therapeutics Holdings Inc. from a group of shareholders for $47.9 million.	02/22/02	CI

Chart Entasis Therapeutics Holdings Inc.

Duration

Period

Chart Entasis Therapeutics Holdings Inc.

More charts

Company Profile

Entasis Therapeutics Holdings Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of targeted antibacterial products that address unmet medical needs to treat infections caused by multidrug-resistant pathogens. Its lead product candidate is sulbactam-durlobactam (SUL-DUR), which is an intravenous, combination of sulbactam, an IV b-lactam antibiotic, and durlobactam, a novel broad-spectrum IV b -lactamase inhibitor (BLI) for the treatment of pneumonia and bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii. Its second late-stage product candidate is zoliflodacin, which is an orally administered molecule being developed for the treatment of uncomplicated gonorrhea. Its third product candidate is ETX0282CPDP for the oral treatment of urinary tract infections. ETX0282CPDP is a combination of ETX0282, a novel oral BLI, with cefpodoxime proxetil (cefpodoxime), an oral b-lactam antibiotic.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+9.85%	12TCr
REGENERON PHARMACEUTICALS, INC.	+10.14%	11TCr
BIONTECH SE	-11.64%	2.34TCr
ARGENX SE	-1.69%	2.21TCr
GENMAB A/S	-10.23%	1.83TCr
WUXI APPTEC CO., LTD.	-41.92%	1.66TCr
BEIGENE, LTD.	-15.51%	1.6TCr
NEUROCRINE BIOSCIENCES, INC.	+6.39%	1.4TCr
SAREPTA THERAPEUTICS, INC.	+16.23%	1.17TCr

Bio Therapeutic Drugs